Edition:
United Kingdom

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

20.15HKD
23 May 2018
Change (% chg)

HK$0.15 (+0.75%)
Prev Close
HK$20.00
Open
HK$20.10
Day's High
HK$20.70
Day's Low
HK$19.80
Volume
5,064,573
Avg. Vol
8,636,589
52-wk High
HK$20.70
52-wk Low
HK$9.35

Chart for

About

3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products.... (more)

Overall

Beta: --
Market Cap(Mil.): HK$34,730.74
Shares Outstanding(Mil.): 2,538.80
Dividend: --
Yield (%): --

Financials

  1530.HK Industry Sector
P/E (TTM): 36.71 30.95 32.75
EPS (TTM): 0.37 -- --
ROI: 8.84 14.84 14.38
ROE: 12.82 16.34 16.07

BRIEF-3SBio Announces Tpiao Injection gets Approval For Clinical Trials For Additional Indication By CFDA

* TPIAO INJECTION GRANTED APPROVAL FOR CLINICAL TRIALS FOR ADDITIONAL INDICATION BY CHINA FOOD AND DRUG ADMINISTRATION​ Source text for Eikon: Further company coverage:

22 Feb 2018

BRIEF-3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​

* UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​ Source text for Eikon: Further company coverage:

15 Jan 2018

BRIEF-3SBio Says ‍China FDA Approves New Once-Weekly Bydureon To Improve Glycemic Control​

* ‍CHINA FDA APPROVES NEW ONCE-WEEKLY BYDUREON TO IMPROVE GLYCEMIC CONTROL​ Source text for Eikon: Further company coverage:

04 Jan 2018

Earnings vs. Estimates